A Trial of One-week on/One-week Off Temozolomide Versus Continuous Dose-Intense Temozolomide in Patients With Glioblastoma Multiforme at First Relapse

NCT02330991 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

204

Enrollment

OTHER

Sponsor class

Conditions

Glioblastoma

Interventions

DRUG: Temozolomide

Sponsor

Beijing Sanbo Brain Hospital